Article

The Antimicrobial efficacy of Elaeis guineensis: characterization, in vitro and in vivo studies.

Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia.
Molecules (impact factor: 2.39). 01/2012; 17(5):4860-77. DOI:10.3390/molecules17054860
Source: PubMed

ABSTRACT The urgent need to treat multi-drug resistant pathogenic microorganisms in chronically infected patients has given rise to the development of new antimicrobials from natural resources. We have tested Elaeis guineensis Jacq (Arecaceae) methanol extract against a variety of bacterial, fungal and yeast strains associated with infections. Our studies have demonstrated that E. guineensis exhibits excellent antimicrobial activity in vitro and in vivo against the bacterial and fungal strains tested. A marked inhibitory effect of the E. guineensis extracts was observed against C. albicans whereby E. guineensis extract at ½, 1, or 2 times the MIC significantly inhibited C. albicans growth with a noticeable drop in optical density (OD) of the bacterial culture. This finding confirmed the anticandidal activity of the extract on C. albicans. Imaging using scanning (SEM) and transmission (TEM) electron microscopy was done to determine the major alterations in the microstructure of the extract-treated C. albicans. The main abnormalities noted via SEM and TEM studies were the alteration in morphology of the yeast cells. In vivo antimicrobial activity was studies in mice that had been inoculated with C. albicans and exhibited good anticandidal activity. The authors conclude that the extract may be used as a candidate for the development of anticandidal agent.

0 0
 · 
0 Bookmarks
 · 
67 Views
  • Article: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
    [show abstract] [hide abstract]
    ABSTRACT: The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.
    Clinical Infectious Diseases 12/2008; 48(1):1-12. · 9.15 Impact Factor
  • Source
    Article: Anti-infective research and development--problems, challenges, and solutions.
    The Lancet Infectious Diseases 02/2007; 7(1):68-78. · 17.39 Impact Factor
  • Article: Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009.
    [show abstract] [hide abstract]
    ABSTRACT: A survey was performed among European intensive care physicians to obtain information about their perception and experience with selected antibiotic-resistant bacteria. Seventy-eight out of 95 (82%) participants considered having to deal with infections due to antibiotic-resistant bacteria in the intensive care unit where they work was a major or significant problem. Methicillin-resistant Staphylococcus aureus (MRSA) and third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently reported antibiotic-resistant bacteria with 69 (73%) and 67 (71%) participants reporting having treated at least one patient with such an infection during the preceding six months, respectively. Antibiotic-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae, were more frequently reported than any selected antibiotic-resistant Gram-positive bacteria, with the exception of MRSA. Fifty (53%) participants declared having treated at least one patient infected with a bacterium totally or almost totally resistant to available antibiotics during the past six months, with 8 participants having treated more than 10 such patients and 13 having treated from 3 to 10 such patients.
    Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 01/2009; 14(45). · 6.15 Impact Factor

Full-text

View
29 Downloads
Available from
31 Oct 2012

Keywords

2 times
 
anticandidal activity
 
anticandidal agent
 
Arecaceae
 
C. albicans
 
E. guineensis
 
E. guineensis exhibits excellent antimicrobial activity
 
Elaeis guineensis Jacq
 
exhibited good anticandidal activity
 
extract-treated C. albicans
 
fungal strains
 
major alterations
 
marked inhibitory effect
 
MIC
 
multi-drug resistant pathogenic microorganisms
 
new antimicrobials
 
optical density
 
TEM studies
 
vivo antimicrobial activity
 
yeast cells